Bank of America Corp DE Boosts Stock Position in Denali Therapeutics Inc. $DNLI
Bank of America Corp DE increased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 21.7% in the first quarter, now holding 1.13 million shares valued at approximately $21.8 million. Institutional investors collectively own 92.92% of DNLI, and analysts maintain a "Moderate Buy" rating with an average target price of $35.92. Despite missing EPS estimates, Denali exceeded revenue expectations and continues to develop therapies for neurodegenerative diseases.
Denali Therapeutics (DNLI) Could Be 42% Undervalued Following Its Earnings Report
Denali Therapeutics (DNLI) reported Q2 2026 revenue of US$3.6 million and a net loss of US$127.55 million. While the company's shares have shown strong recent momentum, trading at US$24.40, there are conflicting views on its valuation, with one narrative suggesting it's 41.9% undervalued at $42.00, while a DCF model indicates it's expensive at its current price. The company's valuation is heavily influenced by the performance of its AVLAYAH product and the pipeline risks.
SCS Capital Management LLC Takes Position in Denali Therapeutics Inc. $DNLI
SCS Capital Management LLC has acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 197,998 shares valued at approximately $5.1 million. This makes them a new institutional investor in the biopharmaceutical company, which has seen significant interest from other large institutional investors as well. Denali Therapeutics maintains a "Moderate Buy" consensus rating from analysts, with a target price of $35.92, despite a recent earnings per share miss.
Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund
Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, Watts maintains significant direct and indirect ownership in the company through a family trust and directly held shares, including unvested RSUs.
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
Denali Therapeutics reported Q2 2026 earnings, highlighting its transition to a commercial-stage company following the successful launch of AVLAYAH, a new therapy for Hunter syndrome. The company achieved $3.6 million in net product revenue in its first full commercial quarter and provided Q3 guidance of $10 million to $12 million due to strong demand and expanding payer coverage. Denali also advanced its Alzheimer's disease programs, DNL628 and DNL921, into clinical development, with initial data expected in 2027, and maintains a strong financial position with over $1.1 billion in cash and marketable securities.
Denali Therapeutics (NASDAQ:DNLI) Insider Sells $71,624.99 in Stock
Denali Therapeutics (NASDAQ:DNLI) insider Alexander Schuth sold 2,857 shares of the company's stock for approximately $71,625, reducing his position by 1% while still holding over 281,000 shares. Despite the company missing analysts' EPS estimates with a quarterly loss of $0.68 per share, revenue exceeded expectations, and the stock is trading near its 52-week high of $27.30. Analysts maintain a "Moderate Buy" rating with an average price target of $35.92, indicating potential upside.
Sei Investments Co. Purchases Shares of 52,235 Denali Therapeutics Inc. $DNLI
Sei Investments Co. has acquired 52,235 shares of Denali Therapeutics Inc. (NASDAQ:DNLI) valued at approximately $1.0 million, contributing to institutional investors' 92.92% ownership of the company. Despite reporting a quarterly loss of $0.68 per share, Denali's revenue exceeded expectations, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $35.92. The stock opened at $25.27 and saw a 2.3% increase.
E. Ohman J or Asset Management AB Acquires New Shares in Denali Therapeutics Inc. $DNLI
E. Ohman J or Asset Management AB recently acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI), purchasing 160,000 shares valued at approximately $4.1 million, giving them a 0.10% stake in the company. Institutional investors collectively own 92.92% of DNLI, with several other hedge funds also adjusting their positions. Analysts maintain a "Moderate Buy" consensus rating for the stock, with an average price target of $35.92, despite the company reporting a quarterly loss of $0.68 per share, which missed estimates.
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction
Baillie Gifford reduced its stake in Denali Therapeutics Inc (DNLI) by 106,249 shares on June 30, 2026, lowering its total holdings to 11,960,230 shares. This transaction, representing a minor -0.88% change in the firm's portfolio, reflects a continued focus on long-term growth by the century-old investment firm. Denali Therapeutics, a biotechnology company focused on neurodegenerative diseases, faces financial challenges with a low GF Score and profitability rank, despite strong momentum and low bankruptcy risk.
Denali climbs past Avlayah expectations with $3.6M in revenue
Denali Therapeutics has exceeded analyst expectations with its new Hunter syndrome therapy, Avlayah, reporting $3.6 million in revenue during its first quarter on the market, significantly surpassing the anticipated $1.3 million. The company has raised its third-quarter revenue guidance to $10-$12 million, driven by strong patient uptake, particularly switches from Takeda's Elaprase. Avlayah marks the first new treatment for Hunter syndrome in 20 years and also represents the first approval for Denali’s TransportVehicle blood-brain barrier technology, with projections for it to reach blockbuster status globally.
The Manufacturers Life Insurance Company Lowers Stock Holdings in Denali Therapeutics Inc. $DNLI
The Manufacturers Life Insurance Company significantly reduced its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 31.9% in the first quarter, selling 58,796 shares and retaining 125,442 shares valued at approximately $2.4 million. Despite this, institutional investors collectively own 92.92% of the stock, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $35.92, exceeding the current share price of $24.83. Denali, a clinical-stage biopharmaceutical company focusing on neurodegenerative diseases, reported a wider-than-expected quarterly loss but surpassed revenue estimates.
(DNLI) Movement Within Algorithmic Entry Frameworks
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models, highlighting strong sentiment across all time horizons and an exceptional 41.9:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes sophisticated risk management and multi-timeframe signal analysis for near-term, mid-term, and long-term outlooks.
Denali Therapeutics (DNLI) Is Up 7.9% After AVLAYAH Launch Drives First Full-Quarter Commercial Revenue
Denali Therapeutics (DNLI) saw its shares rise 7.9% after reporting Q2 2026 results, which included the first full-quarter commercial revenue from its drug AVLAYAH. Despite a net loss of US$127.55 million, the company highlighted growing operational and financial platforms due to AVLAYAH's launch, expanded payer access, and over US$1.10 billion in pro forma cash. The article discusses Denali's investment narrative, emphasizing the need for its TransportVehicle platform to translate science into a viable business, while acknowledging risks like commercialization execution and clinical setbacks.
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of "Moderate Buy" by Analysts
Analysts have issued a "Moderate Buy" consensus rating for Denali Therapeutics Inc. (NASDAQ:DNLI), with an average 12-month price target of $35.92, significantly above its current trading price. This comes despite the company reporting a quarterly loss of $0.68 per share, which missed consensus estimates, although its revenue exceeded expectations. Institutional investors hold a substantial 92.92% stake in the company, with notable increases in holdings from firms like Goldman Sachs.
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Denali Therapeutics (NASDAQ:DNLI) from a "sell" to a "hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average price target of $35.92. Despite missing quarterly EPS estimates, Denali reported higher-than-forecast revenue, and institutional investors hold a significant portion of its stock. The company is trading at $24.83, with a market capitalization of approximately $3.94 billion.
Denali Therapeutics Inc. Stock 12‑Month Price Target Raised to $35.44, Implies 43% Upside
The average 12-month price target for Denali Therapeutics Inc. (DNLI) stock has been raised to $35.44 from $34.31 by 16 analysts, with forecasts ranging from $27 to $42 per share. This new target implies a potential upside of approximately 43% from its August 6 closing price. The consensus rating among 20 analysts remains a "Buy," with 19 Buys and 1 Hold.
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics (DNLI) reported a narrower Q2 2026 loss of 68 cents per share, surpassing the Zacks Consensus Estimate. The company's net product revenues reached $3.6 million, driven by the strong initial commercial sales of its newly FDA-approved drug, Avlayah, for Hunter Syndrome. Denali's stock has seen a significant gain year-to-date, and it projects Avlayah net product revenues of $10.0 million to $12.0 million for Q3 2026.
Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating
Wedbush has increased its price target on Denali Therapeutics Inc. (DNLI) to $27 from $26, while maintaining an Outperform rating. This adjustment comes shortly after Denali Therapeutics reported its Q2 2026 earnings, posting a loss of $0.68 per share but exceeding revenue expectations with $3.6 million. The company recently completed the sale of a Rare Pediatric Disease Priority Review Voucher for $195 million, contributing to recent financial activities.
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Denali Therapeutics reported strong financial results for Q2 2026, driven by the successful launch of AVLAYAH™, which generated $3.6 million in net product revenue. The company also announced the advancement of two Alzheimer’s disease programs into clinical development and received $195 million from the sale of a Priority Review Voucher, boosting its cash reserves to over $1.1 billion. Denali's TransportVehicle™ platform continues to be a key asset, enabling the delivery of biotherapeutics across the blood-brain barrier.
Denali Therapeutics Inc. 2026: Revenue $3.6M, EPS ($0.68) — 10-Q Summary
Denali Therapeutics Inc. reported second-quarter 2026 financial results, marking its first product revenue of $3.6M from the commercial launch of AVLAYAH, despite continuing to incur a net loss and negative EPS. The company highlighted AVLAYAH's accelerated FDA approval and initial U.S. sales, operational scale-up with a new biomanufacturing facility, and progress in multiple clinical programs. Strategic financings, including the sale of a priority review voucher and a royalty transaction, also supported commercial and R&D activities.
Earnings call transcript: Denali Therapeutics posts Q2 2026 revenue miss as AVLAYAH launch builds
Denali Therapeutics reported a Q2 2026 revenue miss, posting $3.6 million against an expected $11.94 million, and a wider-than-forecast loss of $0.68 per share. Despite the miss, the stock rose in after-hours trading as investors focused on the early, encouraging commercial launch of AVLAYAH, the company's first approved medicine, which generated $3.6 million in its first full commercial quarter. Denali provided Q3 revenue guidance for AVLAYAH between $10 million and $12 million, signaling accelerated growth driven by expanding payer coverage and physician adoption.
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M
Denali Therapeutics Inc. (DNLI) reported Q2 revenue of $3.6 million, significantly surpassing FactSet's estimated $2.2 million. The company is focused on developing biotherapeutics that cross the blood-brain barrier for treating neurological conditions and other diseases. Denali also anticipates Q3 revenue to range between $10.0 million and $12.0 million.
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH
Denali Therapeutics reported a Q2 2026 net loss of $127.6 million and $3.6 million in net product revenue from its newly launched therapy, AVLAYAH, for Hunter syndrome. The company also announced the discontinuation of a Parkinson's disease program (BIIB122/DNL151) after its Phase 2b study failed to meet endpoints, while securing $200 million in synthetic royalty funding and selling a Rare Pediatric Disease Priority Review Voucher for $195 million.
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
Denali Therapeutics Inc. (DNLI) reported a Q2 loss of $0.68 per share, outperforming the Zacks Consensus Estimate of a $0.72 loss. The company also surpassed revenue estimates with $3.6 million, significantly higher than zero revenues a year ago. Despite outperforming the market year-to-date, Denali currently holds a Zacks Rank #4 (Sell) due to unfavorable earnings estimate revisions.
Baillie Gifford & Co (DNLI) reports 7.54% stake in Denali Therapeutics common stock
Baillie Gifford & Co has reported a 7.54% stake in Denali Therapeutics (DNLI) common stock, according to an amended Schedule 13G filing. The investment adviser beneficially owns 11,960,230 shares, holding sole voting power over 11,915,890 shares and sole dispositive power over all 11,960,230 shares as of June 30, 2026. These shares are managed on behalf of various investment advisory clients.
How (DNLI) Movements Inform Risk Allocation Models
This article analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI models to inform risk allocation. It highlights divergent sentiment across time horizons, indicating choppy conditions, and points out a significant 41.3:1 risk-reward setup. The analysis provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Denali Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Denali Therapeutics (NASDAQ: DNLI) has approximately 516 employees worldwide as of March 2026, marking a 14.9% growth since 2023. The company is actively hiring, with 38 job postings in 2026, though this represents a 40% decline from 2025. The workforce is primarily located in the United States, with an average salary of $195,010 and a median employee tenure of 2.3 years.
Denali Therapeutics Completes Sale of Rare Pediatric Disease Priority Review Voucher
Denali Therapeutics announced the completion of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The sale generated gross proceeds of $95 million, which the company intends to use to support its pipeline and operations. This strategic move highlights Denali's efforts to maximize its assets and fund future drug development.
Denali Therapeutics sells priority review voucher for $195 million gross proceeds
Denali Therapeutics has sold its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds to a large pharmaceutical company. This voucher was granted after the FDA approved AVLAYAH (tividenofusp alfa) for Hunter syndrome in March 2026. The transaction officially closed on July 27, 2026.
Denali Therapeutics Inc (DNLI) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for Denali Therapeutics Inc (DNLI), encompassing operating, investing, and financing activities. It presents key financial data, including net income, capital expenditures, and free cash flow over several fiscal quarters. The report also includes FAQs defining different types of cash flow and their significance for investors.
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Denali Therapeutics will report its second quarter 2026 financial results and provide business highlights on August 6, 2026. The company plans to issue a press release after market close, followed by a conference call and webcast for investors and the public. This event will cover the company's financial performance and recent developments.
Denali sets Aug. 6 webcast on medicines crossing the blood-brain barrier
Denali Therapeutics (Nasdaq: DNLI) will report its second quarter 2026 financial results and business highlights on Thursday, August 6, 2026. Management will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The company is known for developing biotherapeutics that cross the blood-brain barrier using its proprietary TransportVehicle platform.
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
Denali Therapeutics Inc. announced it will report its Q2 2026 financial results and business highlights on Thursday, August 6, 2026. The report will be followed by a conference call and webcast hosted by Denali's management to discuss the results and provide a general business update. The biotechnology company focuses on developing biotherapeutics for neurodegenerative diseases and lysosomal storage disorders.
DNLI|Denali Therapeutics Inc|Price:23.570|Chg%:+0.460
This article provides a comprehensive stock analysis of Denali Therapeutics Inc (DNLI), highlighting its relatively weak fundamentals but high growth potential. The company is considered fairly valued within the Biotechnology & Medical Research industry, with high institutional ownership and multiple 'Buy' analyst ratings. Denali Therapeutics is focused on developing therapies for neurodegenerative and lysosomal storage diseases, leveraging its Transport Vehicle (TV) technology.
Denali Therapeutics Inc (DNLI) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Denali Therapeutics Inc (DNLI), listing its major shareholders and their respective proportions, including Baillie Gifford & Co., BlackRock Institutional Trust Company, N.A., and T. Rowe Price Investment Management, Inc. It also breaks down shareholder types by proportion, such as investment advisors and hedge funds. Furthermore, the article provides institutional shareholding trends over several quarters and lists related ETFs holding DNLI shares.
Denali Therapeutics Inc. Revenue Breakdown – NASDAQ:DNLI
This article provides a brief overview of Denali Therapeutics Inc. (NASDAQ: DNLI) financials, specifically focusing on its revenue breakdown. It highlights that detailed revenue segmentation by source and country is available, powered by data from ICE Data Services and FactSet. The content is primarily an introductory page from TradingView, offering access to more in-depth financial data.
Denali Therapeutics Inc (DNLI) Valuation: PE, PB & Fair Value Analysis
Denali Therapeutics Inc (DNLI) currently holds a valuation score of 7.56, placing it 225th out of 386 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -8.02, which represents a significant fluctuation compared to its recent high and low. Other key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company.
DNLI|Denali Therapeutics Inc|Price:23.110|Chg%:-0.310
Denali Therapeutics Inc (DNLI) is a biopharmaceutical company focused on neurodegenerative and lysosomal storage diseases, with a current stock price of $23.110. The company's fundamentals are weak, but its growth potential is high, and it is considered fairly valued by analysts. Despite recent weak stock market performance, multiple analysts rate it as a "Buy" with a target price of $34.67, suggesting an upside of over 45%.
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $36
Morgan Stanley has reiterated its Buy rating for Denali Therapeutics (DNLI.US) and increased its target price to $36. This updated target suggests a positive outlook for the company's stock from the investment bank.
DNLI Maintained by Morgan Stanley -- Price Target Raised to $36
Morgan Stanley analyst Matthew Harrison maintained an "Overweight" rating on Denali Therapeutics (DNLI) and increased the price target from $35.00 to $36.00. While the company demonstrates financial strength and momentum, its low profitability and valuation scores suggest caution for investors. Denali Therapeutics, a biotechnology company focusing on neurodegenerative diseases, currently has a GF Score of 34/100.
Denali Therapeutics (DNLI) Stock May Trade At A 12% Premium Following AAIC 2026 Plenary News
Denali Therapeutics (DNLI) has seen a 63.4% return over the past year, but valuation models suggest its stock is currently trading at a premium. Both a Discounted Cash Flow (DCF) analysis and Price-to-Book (P/B) ratio indicate the company is overvalued, with the DCF model suggesting an 11.8% premium relative to its intrinsic value. Investors' willingness to pay this premium may be influenced by excitement surrounding Denali's progress in neurodegenerative diseases and upcoming presentations at AAIC 2026.
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval?
Denali Therapeutics (DNLI) has seen a 71.8% return over the past year, but valuation checks suggest it's currently overvalued. Both the Discounted Cash Flow (DCF) model and Price-to-Book (P/B) ratio indicate the stock is trading at a premium, even though the recent FDA approval of Avlayah has fueled investor interest. Investors are paying more than the sector norm for net assets, and the company's future performance hinges on its ability to translate its pipeline and new commercial footing into consistently growing cash flows.
Denali Therapeutics stock trades steady as ALS program advances and cash position supports pipeline
Denali Therapeutics (DNLI) stock remains steady, driven by advancements in its ALS program (DNL343) and a strong cash position of $1.30 billion as of March 31, 2024. The company reported a 50% year-over-year revenue increase in Q1 2024, reaching $120 million, largely due to collaboration revenue, and a narrowing net loss despite heavy R&D investments. Denali's diverse pipeline, including Parkinson's and Alzheimer's collaborations, and its financial flexibility are key factors supporting investor confidence.
Denali Therapeutics (DNLI) Heads To Alzheimer’s Conference As Valuation Questions Return
Denali Therapeutics (DNLI) is poised to present at an Alzheimer's conference, drawing attention to its neurodegenerative disease research pipeline. While the stock has seen a 66.36% increase over the past year, it remains about 47% below the average analyst price target, raising valuation questions. The company's price-to-book ratio of 4x is noteworthy given its current losses, and a Discounted Cash Flow model suggests the stock may be slightly overvalued, prompting investors to consider both balance sheet comparisons and cash flow models.
Deutsche Bank Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $35
Deutsche Bank has reiterated its Buy rating on Denali Therapeutics (DNLI.US) and increased its target price for the stock to $35. This revised target price suggests a potential upside for investors, reflecting Deutsche Bank's positive outlook on the company's future performance.
Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC)
Two healthcare companies, Denali Therapeutics (DNLI) and Celcuity (CELC), have received bullish ratings from analysts. Denali Therapeutics secured a Strong Buy consensus with a significant upside, while Celcuity also garnered a Strong Buy with a high price target. These recommendations highlight strong analyst confidence in the growth prospects of both companies within the healthcare sector.
DENALI THERAPEUTICS INC. : DEUTSCHE BANK RAISES TARGET PRICE TO $35 FROM $31
Deutsche Bank has increased its target price for Denali Therapeutics Inc. (DNLI.O) to $35 from $31. This update reflects an analyst's revised outlook on the company's financial prospects. The information is provided by Reuters and should not be taken as investment advice.
Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating
Deutsche Bank has increased its price target for Denali Therapeutics (DNLI) to $35 from $31, while reiterating a "Buy" rating on the stock. This adjustment reflects an updated outlook by the bank on the biopharmaceutical company, which specializes in therapies for neurodegenerative diseases. The article also mentions recent news and analyst actions related to Denali Therapeutics, including Biogen's Alzheimer's drug results and other analyst price target changes.
Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan
JP Morgan has set a price target of $29.00 per share for Denali Therapeutics, indicating their valuation of the company's stock. This announcement provides investors with an analyst's perspective on the potential future trading price of Denali Therapeutics.
Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating
Wedbush has increased its price target for Denali Therapeutics (NASDAQ: DNLI) from $20 to $26, while maintaining an Outperform rating on the stock. This adjustment reflects Wedbush's continued positive outlook on the company's prospects.
